Goh S et al. |
An integrative expression vector for Actinosynnema pretiosum. |
2007 |
BMC Biotechnol. |
pmid:17956638
|
Kan S et al. |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. |
2015 |
BMC Cancer |
pmid:26475267
|
Barok M et al. |
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. |
2018 |
BMC Cancer |
pmid:29720111
|
Ricciardi GRR et al. |
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. |
2018 |
BMC Cancer |
pmid:29370839
|
Tripathy D et al. |
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. |
2014 |
BMC Cancer |
pmid:24885258
|
Tang R et al. |
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. |
2009 |
BMC Cancer |
pmid:19549303
|
Mitsuya K et al. |
Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. |
2016 |
BMC Cancer |
pmid:27377061
|
Kmietowicz Z |
NICE approves trastuzumab emtansine after deal with drug company. |
2017 |
BMJ |
pmid:28623237
|
Dixon JM et al. |
HER2 testing in patients with breast cancer. |
2012 |
BMJ |
pmid:22689887
|
White C |
NICE confirms advanced breast cancer drug is too expensive for NHS. |
2014 |
BMJ |
pmid:25106642
|
Torres S et al. |
Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. |
2014 |
BMJ Case Rep |
pmid:25123575
|
Daniels B et al. |
Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. |
2017 |
BMJ Open |
pmid:28119394
|
Chen SC et al. |
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. |
2017 |
Br J Clin Pharmacol |
pmid:28733983
|
Coiffier B et al. |
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. |
2016 |
Br. J. Haematol. |
pmid:27010483
|
Ishitsuka K et al. |
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. |
2008 |
Br. J. Haematol. |
pmid:18279455
|
Ghetti B |
Induction of neurofibrillary degeneration following treatment with maytansine in vivo. |
1979 |
Brain Res. |
pmid:581857
|
Ghetti B and Gambetti P |
Comparative immunocytochemical characterization of neurofibrillary tangles in experimental maytansine and aluminum encephalopathies. |
1983 |
Brain Res. |
pmid:6354362
|
Escrivá-de-Romanà S et al. |
HER2-positive breast cancer: Current and new therapeutic strategies. |
2018 |
Breast |
pmid:29631097
|
Barroso-Sousa R et al. |
Biological therapies in breast cancer: common toxicities and management strategies. |
2013 |
Breast |
pmid:24144949
|
Ahmed S et al. |
HER2-directed therapy: current treatment options for HER2-positive breast cancer. |
2015 |
Breast Cancer |
pmid:25634227
|